bpc 157 dopamine Development of a peptide targeting transporter to improve ADHD-like deficits | Molecular Brain Michael Morelli | BPC-157 may

The mechanism is largely angiogenic: BPC-157 upregulates VEGF (vascular endothelial growth factor) and activates VEGFR2, stimulating the formation of new blood vessels in damaged tissue

For example, dramatically improved glucose could mask an underlying insulin resistance pattern that resurfaces if the medication is stopped

No Rebound Hunger or Metabolic Adaptation Appetite suppressants that work through central mechanisms (GLP-1 agonists, sympathomimetics, serotonergic agents) typically create tolerance over time, requiring dose escalation, and often produce rebound hunger when discontinued

Interestingly, while BPC-157 promotes healing-associated angiogenesis, research also demonstrates it can inhibit tumor-promoting effects of VEGF signaling via the MAPK pathway in melanoma cell lines, suggesting context-dependent modulation of vascular growth that may preferentially support physiological tissue repair over pathological neovascularization